http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110903397-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
| filingDate | 2019-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110903397-B |
| titleOfInvention | PCSK9-specific fully human antibody with reduced low-density lipoprotein and its application |
| abstract | The invention relates to the technical field of biotechnology, and discloses a PCSK9-specific fully human antibody capable of reducing low-density lipoprotein (LDL) and an application thereof. The amino acid sequence of the variable region of the light chain of the antibody is shown in SEQ ID NO: 1 , the amino acid sequence of the variable region of the antibody heavy chain is shown in SEQ ID NO: 2. Through in vitro cytological tests and in vivo tests in model mice, it is preliminarily confirmed that the fully human antibody provided by the present invention can regulate the number of low-density lipoprotein receptors (LDLR) on the cell surface, regulate the uptake of LDL by cells, and regulate the model mice. The concentration level of low-density lipoprotein cholesterol (LDL-C) in the blood, it can be seen that the present invention lays a core raw material basis for preparing a cholesterol-lowering preparation targeting PCSK9. |
| priorityDate | 2019-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 455.